同种异体造血干细胞移植后发热性中性粒细胞减少症的有效移植:粒细胞输注作为桥梁治疗。

IF 3.4 3区 医学 Q2 HEMATOLOGY
Therapeutic Advances in Hematology Pub Date : 2025-03-22 eCollection Date: 2025-01-01 DOI:10.1177/20406207251326765
Neslihan Mandaci Şanli, Ali Ünal
{"title":"同种异体造血干细胞移植后发热性中性粒细胞减少症的有效移植:粒细胞输注作为桥梁治疗。","authors":"Neslihan Mandaci Şanli, Ali Ünal","doi":"10.1177/20406207251326765","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is crucial for treating high-risk hematological cancers. Posttransplant infections are a leading cause of mortality and morbidity, especially before engraftment. This study evaluated the effects of granulocyte transfusion (GT) therapy on neutrophil and platelet (PLT) engraftment in patients with febrile neutropenia during the pre-engraftment phase following allo-HSCT with a control group.</p><p><strong>Methods: </strong>We retrospectively analyzed 56 patients who underwent allo-HSCT from January 2019 to January 2024, dividing them into two groups: those who received GT (GTG) and those who did not (non-GTG).</p><p><strong>Results: </strong>A total of 76 GTs were administered to 28 patients with febrile neutropenia during the pre-engraftment period. The median granulocyte dose was 5.4 × 10<sup>8</sup>/kg. Median engraftment times in the GTG were 13 days for both PLT and neutrophil engraftment, compared to 15.5 days (PLT) and 19 days (neutrophil) in the non-GTG (<i>p</i> < 0.001 for neutrophil and <i>p</i> = 0.007 for PLT). Additionally, 89.3% of patients in the GTG showed improved infection status. Overall survival (OS) at 2 year was 61.4% for GTG and 73.2% for non-GTG, respectively. No significant difference in OS between the groups (<i>p</i> > 0.05). In the non-GTG, the OS rate was 47.5%, with no significant difference in OS and mortality rates between the groups. GT did not affect the incidence of graft-versus-host disease or cytomegalovirus infection.</p><p><strong>Conclusion: </strong>This study is the first to include a control group and demonstrate a statistically significant association between GT therapy in the pre-engraftment period and shortened engraftment times in allo-HSCT recipients.</p>","PeriodicalId":23048,"journal":{"name":"Therapeutic Advances in Hematology","volume":"16 ","pages":"20406207251326765"},"PeriodicalIF":3.4000,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11946294/pdf/","citationCount":"0","resultStr":"{\"title\":\"Effective engraftment via granulocyte transfusion in pre-engraftment febrile neutropenia following allogeneic hematopoietic stem cell transplantation: granulocyte transfusion as bridge therapy.\",\"authors\":\"Neslihan Mandaci Şanli, Ali Ünal\",\"doi\":\"10.1177/20406207251326765\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is crucial for treating high-risk hematological cancers. Posttransplant infections are a leading cause of mortality and morbidity, especially before engraftment. This study evaluated the effects of granulocyte transfusion (GT) therapy on neutrophil and platelet (PLT) engraftment in patients with febrile neutropenia during the pre-engraftment phase following allo-HSCT with a control group.</p><p><strong>Methods: </strong>We retrospectively analyzed 56 patients who underwent allo-HSCT from January 2019 to January 2024, dividing them into two groups: those who received GT (GTG) and those who did not (non-GTG).</p><p><strong>Results: </strong>A total of 76 GTs were administered to 28 patients with febrile neutropenia during the pre-engraftment period. The median granulocyte dose was 5.4 × 10<sup>8</sup>/kg. Median engraftment times in the GTG were 13 days for both PLT and neutrophil engraftment, compared to 15.5 days (PLT) and 19 days (neutrophil) in the non-GTG (<i>p</i> < 0.001 for neutrophil and <i>p</i> = 0.007 for PLT). Additionally, 89.3% of patients in the GTG showed improved infection status. Overall survival (OS) at 2 year was 61.4% for GTG and 73.2% for non-GTG, respectively. No significant difference in OS between the groups (<i>p</i> > 0.05). In the non-GTG, the OS rate was 47.5%, with no significant difference in OS and mortality rates between the groups. GT did not affect the incidence of graft-versus-host disease or cytomegalovirus infection.</p><p><strong>Conclusion: </strong>This study is the first to include a control group and demonstrate a statistically significant association between GT therapy in the pre-engraftment period and shortened engraftment times in allo-HSCT recipients.</p>\",\"PeriodicalId\":23048,\"journal\":{\"name\":\"Therapeutic Advances in Hematology\",\"volume\":\"16 \",\"pages\":\"20406207251326765\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-03-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11946294/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Hematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/20406207251326765\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20406207251326765","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:同种异体造血干细胞移植(allogene hematopoietic stem cell transplantation, alloo - hsct)是治疗高危血液病的关键。移植后感染是导致死亡和发病的主要原因,尤其是在移植前。本研究评估了粒细胞输注(GT)治疗对同种异体造血干细胞移植后植入前期发热性中性粒细胞减少患者中性粒细胞和血小板(PLT)植入的影响。方法:回顾性分析2019年1月至2024年1月56例接受同种异体移植的患者,将其分为两组:接受GT (GTG)和未接受GTG(非GTG)的患者。结果:对28例植入前期发热性中性粒细胞减少患者共进行76次GTs治疗。中位粒细胞剂量为5.4 × 108/kg。在GTG中,PLT和中性粒细胞移植的中位移植时间为13天,而非GTG中位移植时间为15.5天(PLT)和19天(中性粒细胞)(中性粒细胞p < 0.001, PLT p = 0.007)。此外,89.3%的GTG患者感染状况有所改善。GTG组2年总生存率(OS)为61.4%,非GTG组为73.2%。两组间OS差异无统计学意义(p < 0.05)。在非gtg组中,总生存率为47.5%,两组间总生存率和死亡率无显著差异。GT不影响移植物抗宿主病或巨细胞病毒感染的发生率。结论:这项研究首次纳入了一个对照组,并证明了同种异体移植受者在移植前接受GT治疗与缩短移植时间之间存在统计学上显著的关联。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Effective engraftment via granulocyte transfusion in pre-engraftment febrile neutropenia following allogeneic hematopoietic stem cell transplantation: granulocyte transfusion as bridge therapy.

Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is crucial for treating high-risk hematological cancers. Posttransplant infections are a leading cause of mortality and morbidity, especially before engraftment. This study evaluated the effects of granulocyte transfusion (GT) therapy on neutrophil and platelet (PLT) engraftment in patients with febrile neutropenia during the pre-engraftment phase following allo-HSCT with a control group.

Methods: We retrospectively analyzed 56 patients who underwent allo-HSCT from January 2019 to January 2024, dividing them into two groups: those who received GT (GTG) and those who did not (non-GTG).

Results: A total of 76 GTs were administered to 28 patients with febrile neutropenia during the pre-engraftment period. The median granulocyte dose was 5.4 × 108/kg. Median engraftment times in the GTG were 13 days for both PLT and neutrophil engraftment, compared to 15.5 days (PLT) and 19 days (neutrophil) in the non-GTG (p < 0.001 for neutrophil and p = 0.007 for PLT). Additionally, 89.3% of patients in the GTG showed improved infection status. Overall survival (OS) at 2 year was 61.4% for GTG and 73.2% for non-GTG, respectively. No significant difference in OS between the groups (p > 0.05). In the non-GTG, the OS rate was 47.5%, with no significant difference in OS and mortality rates between the groups. GT did not affect the incidence of graft-versus-host disease or cytomegalovirus infection.

Conclusion: This study is the first to include a control group and demonstrate a statistically significant association between GT therapy in the pre-engraftment period and shortened engraftment times in allo-HSCT recipients.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.30
自引率
0.00%
发文量
54
审稿时长
7 weeks
期刊介绍: Therapeutic Advances in Hematology delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of hematology. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in hematology, providing a forum in print and online for publishing the highest quality articles in this area.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信